New cream shows promise for rare skin condition

NCT ID NCT05211830

Completed Disease control Sponsor: Sixera Pharma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a cream called SXR1096 on 9 people with Netherton syndrome, a rare inflammatory skin disease. The cream aims to block certain enzymes that cause skin problems. Participants applied the cream and a placebo to different skin areas for one month to check safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SXR1096 cream
What this could lead to: If it works, this could point toward a treatment that controls the severe skin inflammation in Netherton syndrome.
What could go wrong: This is a very early, small trial with only 9 people. The cream may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Netherton syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NETHERTON SYNDROME

Contacts and locations

Locations

Karolinska Hospital, Huddinge

Stockholm, Sweden
Medical University Innsbruck, Tirol Kliniken

Innsbruck, Austria
Necker Hospital

Paris, France
Saint Louis Hospital

Paris, 75010, France
University of Freiburg

Freiburg im Breisgau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.